Impact of the Inflation Reduction Act on Venture Capital in Life Sciences
In this Vital Health Podcast, John Stanford, Executive Director of Incubate, discusses the impact of the Inflation Reduction Act (IRA) on venture capital investments in life sciences. Stanford emphasizes that the IRA's price control mechanisms have led to significant shifts in funding, particularly away from small-molecule drug development, creating what is described as the "small molecule penalty." Key points include:
Venture Capital's Role and Challenges:
Venture capital is critical in translating basic research into medicines.
The Inflation Reduction Act has disrupted this ecosystem…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.